Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.19.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Current Assets    
Cash and cash equivalents $ 18,650 $ 28,918
Prepaid expenses and other current assets 1,193 593
Total Current Assets 19,843 29,511
Property and equipment, net 425 607
Right of Use Asset 451 0
Deposits and other assets 23 23
Total Assets 20,742 30,141
Current Liabilities:    
Accounts payable 2,452 1,034
Accrued expenses 2,321 919
Accrued employee benefits 619 1,332
Deferred rent 0 99
Lease liability 241 0
Total Current Liabilities 5,633 3,384
Long term deferred rent 0 302
Lease liability - Long term 539 0
Total Liabilities 6,172 3,686
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 120,000 issued and outstanding 12,481 12,296
Stockholders' Equity:    
Common stock, $0.001 par value; 200,000,000 shares authorized, 16,808,758, issued and 16,806,430 outstanding and 15,484,411, issued and 15,482,083 outstanding 17 15
Additional paid-in capital 232,485 230,754
Accumulated deficit (232,394) (219,461)
Total Synthetic Biologics, Inc. and Subsidiaries Equity 4,930 17,068
Non-controlling interest (2,841) (2,909)
Total Stockholders' Equity 2,089 14,159
Total Liabilities and Stockholders' Equity 20,742 30,141
Series B Preferred Stock [Member]    
Stockholders' Equity:    
Series B Convertible Preferred stock, $1,000 par value; 10,000,000 shares authorized, 7,638 issued and outstanding and 9,161 issued and outstanding 4,822 5,760
Total Stockholders' Equity $ 4,822 $ 5,760